AR087091A1 - Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso - Google Patents
Polipeptidos quimericos e hibridos del factor viii, y sus metodos de usoInfo
- Publication number
- AR087091A1 AR087091A1 ARP120102464A ARP120102464A AR087091A1 AR 087091 A1 AR087091 A1 AR 087091A1 AR P120102464 A ARP120102464 A AR P120102464A AR P120102464 A ARP120102464 A AR P120102464A AR 087091 A1 AR087091 A1 AR 087091A1
- Authority
- AR
- Argentina
- Prior art keywords
- factor viii
- subject
- chain
- administering
- level
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un método de administrar Factor VIII a un sujeto que lo necesita, que comprende administrar al sujeto una dosis terapéutica de un polipéptido quimérico que comprende una porción del Factor VIII y una segunda porción en un intervalo de dosis al menos aproximadamente una y medio veces más largo que el intervalo de dosis requerido para una dosis equivalente de un polipéptido que consiste en dicha porción del Factor VIII, donde dicha porción del Factor VIII comprende el Factor VIII procesado, que tiene dos cadenas, una primera cadena que comprende una cadena pesada y una segunda cadena que comprende una cadena liviana, donde dicha primera cadena y dicha segunda cadena se asocian con un enlace metálico. Reivindicación 39: Una composición que comprende un polipéptido quimérico que tiene actividad de Factor VIII, donde al menos aproximadamente 30%, aproximadamente 40%, aproximadamente 50%, aproximadamente 60%, aproximadamente 70%, aproximadamente 80%, aproximadamente 90%, aproximadamente 95%, aproximadamente 96%, aproximadamente 97%, aproximadamente 98%, aproximadamente 99%, o aproximadamente 100% de dicho polipéptido comprende a porción del Factor VIII, que es el Factor VIII de cadena simple, y una segunda porción, donde dicho Factor VIII de cadena simple es al menos 90% ó 95% idéntica a una secuencia de aminoácidos del Factor VIII que se muestra en la Tabla 2 sin una secuencia señal (aminoácidos 20 a 1457 de la SEQ ID Nº 2 o aminoácidos 20 a 2351 de la SEQ ID Nº 6). Reivindicación 73: Un método de tratar una afección de sangrado que comprende administrar una cantidad terapéuticamente efectiva de la composición de acuerdo con cualquiera de las reivindicaciones 39 - 72. Reivindicación 81: Un método de mantener el Factor VIII en una población de pacientes a un nivel superior a 1% durante al menos un día, dos días, o tres días que comprende administrar una cantidad terapéuticamente efectiva de rFVIIIFc a dicha población, donde la cantidad terapéuticamente efectiva es al menos 25 IU/kg de rFVIIIFc y donde al menos 90% de dicha población mantiene el nivel mínimo del Factor VIII al menos 1% o más. Reivindicación 105: Un método de prevenir, disminuir, o tratar un episodio de sangrado en un sujeto que comprende: (a) identifican un sujeto que tiene niveles altos de VWF por la medición del nivel de VWF en el plasma de dicho sujeto, donde un nivel de VWF de al menos aproximadamente 100 IU/dL identifica el sujeto que tiene un alto nivel de VWF; y (b) administrar al sujeto una cantidad efectiva de una proteína de FVIII de acción prolongada.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506015P | 2011-07-08 | 2011-07-08 | |
US201161522647P | 2011-08-11 | 2011-08-11 | |
US201161541561P | 2011-09-30 | 2011-09-30 | |
US201161569158P | 2011-12-09 | 2011-12-09 | |
US201261586443P | 2012-01-13 | 2012-01-13 | |
US201261622789P | 2012-04-11 | 2012-04-11 | |
US201261657641P | 2012-06-08 | 2012-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087091A1 true AR087091A1 (es) | 2014-02-12 |
Family
ID=47506823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102464A AR087091A1 (es) | 2011-07-08 | 2012-07-06 | Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso |
Country Status (27)
Country | Link |
---|---|
US (3) | US10010622B2 (es) |
EP (3) | EP3513804B1 (es) |
JP (5) | JP2014522838A (es) |
KR (2) | KR102110736B1 (es) |
CN (2) | CN103796670A (es) |
AR (1) | AR087091A1 (es) |
AU (3) | AU2012282875B2 (es) |
BR (1) | BR112014000466A2 (es) |
CA (1) | CA2841066C (es) |
CL (1) | CL2014000024A1 (es) |
CO (1) | CO6940381A2 (es) |
CY (1) | CY1122900T1 (es) |
DK (2) | DK2729161T3 (es) |
EA (1) | EA029045B1 (es) |
ES (2) | ES2722209T3 (es) |
HR (2) | HRP20220639T1 (es) |
HU (1) | HUE043763T2 (es) |
IL (2) | IL230333B (es) |
LT (2) | LT3513804T (es) |
MX (1) | MX350581B (es) |
MY (1) | MY180714A (es) |
PL (2) | PL2729161T3 (es) |
PT (2) | PT2729161T (es) |
RS (2) | RS58578B1 (es) |
SI (2) | SI2729161T1 (es) |
TW (3) | TWI626947B (es) |
WO (1) | WO2013009627A2 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3552627A1 (en) * | 2003-05-06 | 2019-10-16 | Bioverativ Therapeutics Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
CN105838699A (zh) | 2006-12-15 | 2016-08-10 | 巴克斯艾尔塔公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CN104530182A (zh) | 2009-07-27 | 2015-04-22 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
CA2769244A1 (en) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
JP5908401B2 (ja) | 2009-07-27 | 2016-04-26 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 血液凝固タンパク質複合体 |
CA2782424C (en) | 2009-12-06 | 2021-07-27 | Biogen Idec Hemophilia Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
SG191298A1 (en) | 2010-12-22 | 2013-07-31 | Baxter Int | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
ES2722209T3 (es) * | 2011-07-08 | 2019-08-08 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos e híbridos del Factor VIII, y métodos de uso de los mismos |
EP2836518B1 (en) | 2012-04-11 | 2019-01-02 | Bioverativ Therapeutics Inc. | Methods of detecting glycosaminoglycans |
AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
EP3693000B1 (en) | 2012-06-08 | 2022-03-02 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
EP2870250B2 (en) | 2012-07-06 | 2022-06-29 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
EP3943102A1 (en) * | 2012-10-30 | 2022-01-26 | Bioverativ Therapeutics Inc. | Methods of using fviii polypeptide |
HRP20231183T1 (hr) | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimizirani gen faktora viii |
TWI629993B (zh) * | 2013-03-15 | 2018-07-21 | 美商生物化學醫療公司 | 因子viii多肽調配物 |
US10078811B2 (en) | 2013-11-29 | 2018-09-18 | Fedex Corporate Services, Inc. | Determining node location based on context data in a wireless node network |
US10453023B2 (en) | 2014-05-28 | 2019-10-22 | Fedex Corporate Services, Inc. | Methods and node apparatus for adaptive node communication within a wireless node network |
US11238397B2 (en) | 2015-02-09 | 2022-02-01 | Fedex Corporate Services, Inc. | Methods, apparatus, and systems for generating a corrective pickup notification for a shipped item using a mobile master node |
US10491479B2 (en) | 2015-07-08 | 2019-11-26 | Fedex Corporate Services, Inc. | Systems, apparatus, and methods of time gap related monitoring for an event candidate related to an ID node within a wireless node network |
PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
HRP20221089T1 (hr) | 2016-02-01 | 2022-11-25 | Bioverativ Therapeutics Inc. | Optimizirani geni faktora viii |
CA3014870A1 (en) | 2016-03-23 | 2017-09-28 | Fedex Corporate Services, Inc. | Systems, apparatus, and methods for self-adjusting a broadcast setting of a node in a wireless node network |
EP3502143A4 (en) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
CN107759696A (zh) | 2016-08-19 | 2018-03-06 | 安源医药科技(上海)有限公司 | 人白介素7融合蛋白及其制备方法 |
US10603275B2 (en) | 2017-11-07 | 2020-03-31 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
WO2019175381A1 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes |
WO2019175384A2 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
US20210070819A1 (en) | 2018-03-16 | 2021-03-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes |
CN112512551A (zh) * | 2018-03-28 | 2021-03-16 | 奥里尼斯生物科学公司股份有限公司 | 双功能蛋白及其构建 |
JP2021523878A (ja) * | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病aを処置する方法 |
EP3962516A4 (en) * | 2019-05-03 | 2023-01-04 | Rani Therapeutics, LLC | COAGULATION FACTOR PREPARATIONS TO BE DELIVERED INTO INTESTINAL TRACT TISSUE BY MEANS OF A SWALLOWED DRUG DELIVERY DEVICE |
AU2020298233A1 (en) | 2019-06-19 | 2022-01-20 | Bioverativ Therapeutics Inc. | Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4868112A (en) | 1985-04-12 | 1989-09-19 | Genetics Institute, Inc. | Novel procoagulant proteins |
KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
WO1987004187A1 (en) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
WO1990009800A1 (en) | 1989-02-21 | 1990-09-07 | Washington University | Modified forms of reproductive hormones |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
SG89295A1 (en) | 1991-03-15 | 2002-06-18 | Amgen Inc | Pegylation of polypeptides |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
AU2002337901B2 (en) * | 2001-10-05 | 2008-01-17 | Expression Therapeutics Llc | Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
EP3552627A1 (en) | 2003-05-06 | 2019-10-16 | Bioverativ Therapeutics Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
PL1824988T3 (pl) | 2004-11-12 | 2018-01-31 | Bayer Healthcare Llc | Ukierunkowana na miejsce modyfikacja czynnika VIII |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
SG123635A1 (en) | 2004-12-28 | 2006-07-26 | Nanoscience Innovation Pte Ltd | Nanostructured zinc oxide and a method of producing the same |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
AU2007223888A1 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Genetic packages and uses thereof |
JP5448839B2 (ja) * | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
EP2369005B1 (en) | 2007-06-21 | 2013-04-03 | Technische Universität München | Biological active proteins having increased in vivo and/or in vitro stability |
KR20100058541A (ko) | 2007-08-15 | 2010-06-03 | 아뮤닉스 인코포레이티드 | 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법 |
US8239182B2 (en) | 2007-12-04 | 2012-08-07 | Spansion Llc | Data transmission system-on-chip memory model based validation |
ES2730800T3 (es) | 2009-02-03 | 2019-11-12 | Amunix Pharmaceuticals Inc | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
CA2782424C (en) * | 2009-12-06 | 2021-07-27 | Biogen Idec Hemophilia Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
US9611310B2 (en) * | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
EA201291482A1 (ru) * | 2010-07-09 | 2013-10-30 | Байоджен Айдек Хемофилия Инк. | Химерные факторы коагуляции |
ES2722209T3 (es) * | 2011-07-08 | 2019-08-08 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos e híbridos del Factor VIII, y métodos de uso de los mismos |
-
2012
- 2012-07-06 ES ES12811808T patent/ES2722209T3/es active Active
- 2012-07-06 WO PCT/US2012/045784 patent/WO2013009627A2/en active Application Filing
- 2012-07-06 CN CN201280043194.2A patent/CN103796670A/zh active Pending
- 2012-07-06 RS RS20190355A patent/RS58578B1/sr unknown
- 2012-07-06 TW TW101124461A patent/TWI626947B/zh active
- 2012-07-06 MY MYPI2014000038A patent/MY180714A/en unknown
- 2012-07-06 TW TW109104200A patent/TWI764092B/zh active
- 2012-07-06 KR KR1020187003966A patent/KR102110736B1/ko active IP Right Grant
- 2012-07-06 EP EP18211156.7A patent/EP3513804B1/en active Active
- 2012-07-06 EA EA201490039A patent/EA029045B1/ru not_active IP Right Cessation
- 2012-07-06 DK DK12811808.0T patent/DK2729161T3/en active
- 2012-07-06 RS RS20220491A patent/RS63241B1/sr unknown
- 2012-07-06 PT PT12811808T patent/PT2729161T/pt unknown
- 2012-07-06 EP EP12811808.0A patent/EP2729161B1/en active Active
- 2012-07-06 PT PT182111567T patent/PT3513804T/pt unknown
- 2012-07-06 AR ARP120102464A patent/AR087091A1/es not_active Application Discontinuation
- 2012-07-06 PL PL12811808T patent/PL2729161T3/pl unknown
- 2012-07-06 HU HUE12811808A patent/HUE043763T2/hu unknown
- 2012-07-06 CA CA2841066A patent/CA2841066C/en active Active
- 2012-07-06 AU AU2012282875A patent/AU2012282875B2/en active Active
- 2012-07-06 BR BR112014000466A patent/BR112014000466A2/pt not_active Application Discontinuation
- 2012-07-06 US US14/131,600 patent/US10010622B2/en active Active
- 2012-07-06 EP EP22163636.8A patent/EP4169525A1/en active Pending
- 2012-07-06 CN CN201710301935.7A patent/CN107261122A/zh active Pending
- 2012-07-06 LT LTEP18211156.7T patent/LT3513804T/lt unknown
- 2012-07-06 SI SI201231567T patent/SI2729161T1/sl unknown
- 2012-07-06 TW TW106131035A patent/TWI687226B/zh active
- 2012-07-06 JP JP2014519074A patent/JP2014522838A/ja not_active Withdrawn
- 2012-07-06 KR KR1020147003130A patent/KR101829603B1/ko active IP Right Grant
- 2012-07-06 ES ES18211156T patent/ES2913994T3/es active Active
- 2012-07-06 SI SI201232000T patent/SI3513804T1/sl unknown
- 2012-07-06 MX MX2014000202A patent/MX350581B/es active IP Right Grant
- 2012-07-06 DK DK18211156.7T patent/DK3513804T3/da active
- 2012-07-06 LT LTEP12811808.0T patent/LT2729161T/lt unknown
- 2012-07-06 HR HRP20220639TT patent/HRP20220639T1/hr unknown
- 2012-07-06 PL PL18211156T patent/PL3513804T3/pl unknown
-
2014
- 2014-01-06 IL IL230333A patent/IL230333B/en active IP Right Grant
- 2014-01-07 CL CL2014000024A patent/CL2014000024A1/es unknown
- 2014-01-21 CO CO14011134A patent/CO6940381A2/es unknown
-
2016
- 2016-07-15 AU AU2016204986A patent/AU2016204986B2/en active Active
-
2017
- 2017-02-20 JP JP2017028814A patent/JP2017088623A/ja active Pending
-
2018
- 2018-04-27 AU AU2018202936A patent/AU2018202936B2/en active Active
- 2018-05-29 US US15/991,629 patent/US10881742B2/en active Active
- 2018-11-29 JP JP2018223631A patent/JP7273487B2/ja active Active
-
2019
- 2019-03-19 CY CY20191100325T patent/CY1122900T1/el unknown
- 2019-03-19 HR HRP20190535TT patent/HRP20190535T1/hr unknown
-
2020
- 2020-01-06 IL IL271870A patent/IL271870B/en unknown
- 2020-12-04 US US17/112,280 patent/US20210220476A1/en active Pending
-
2021
- 2021-10-18 JP JP2021170188A patent/JP2022003096A/ja not_active Withdrawn
-
2023
- 2023-07-31 JP JP2023124309A patent/JP2023134851A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR087091A1 (es) | Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso | |
CY1123385T1 (el) | Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης | |
CY1122800T1 (el) | Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων | |
AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
CO2018005215A2 (es) | Construcciones específicas del hígado para expresión del factor viii | |
PE20191345A1 (es) | Administracion viral de neoantigenos | |
AR093626A1 (es) | Proteinas de fusion de enzima lisosomal y usos de las mismas | |
AR086998A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
ECSP15014133A (es) | Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida | |
AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
IN2014KN01713A (es) | ||
AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
IN2014KN01714A (es) | ||
AR105822A1 (es) | Análogos de insulina | |
EA201200515A1 (ru) | Полипептиды и их применение | |
GT201700224A (es) | Proteína de unión a rgma y su uso | |
ES2545457T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
AR076977A1 (es) | Proteinas precursoras repetitivas autoensambladas | |
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
CY1118856T1 (el) | Εμβολιο pcsk9 | |
PE20191786A1 (es) | Anticuerpo monoclonal para pd-l1 | |
ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |